Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035784 | 0.98 | PPARG (0.41) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL6036112 | 0.96 | PPARG (0.40) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL6036437 | 0.93 | PPARG (0.41) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL6035119 | 0.93 | SMN1; SMN2 (0.40) | PPARGSMN1; SMN2PPARDPPARAKDM4E | |
| SCHEMBL6034968 | 0.93 | HCRTR1 (0.38) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL1634394 | 0.92 | PPARG (0.40) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL6035762 | 0.92 | PPARG (0.40) | PPARGHCRTR1HCRTR2SMN1; SMN2TSHR | |
| SCHEMBL6035546 | 0.91 | PPARG (0.48) | PPARGSMN1; SMN2TSHRTAAR1ITGB1 | |
| SCHEMBL6035590 | 0.91 | GCGR (0.36) | PPARGHCRTR1HCRTR2SMN1; SMN2PPARD | |
| SCHEMBL6036239 | 0.90 | HDAC4 (0.35) | PPARGHCRTR1HCRTR2SMN1; SMN2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | claimed |
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | PPARG 38/4885HCRTR1 567/4885HCRTR2 464/4885 |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885HCRTR1 215/4885HCRTR2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.